Floatz logo

Synthetic Human Papillomavirus 16 E6 Peptide

Vulvar Cancer

National Cancer Institute (NCI)protein_peptidePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

15 Active assets in the Vulvar Cancer cohort.

Asset / SponsorPhaseRating
Indocyanine Green
Istanbul University
Phase 4BB
TECHNETIUM-99
Institut de Cancérologie de Lorraine
Phase 3B
Octreotide Pamoate
Alliance for Clinical Trials in Oncology
Phase 3B
e7 tcr-t cells
Christian Hinrichs
Phase 2B
Durvalumab
M.D. Anderson Cancer Center
Phase 2B

View all 34 →

Same molecule, other indications

Synthetic Human Papillomavirus 16 E6 Peptide is also rated in:

penile cancerDormant
CC
Indicative ·
44 / 100
View asset →
anal carcinomaDormant
CC
Indicative ·
42 / 100
View asset →
head and neck cancerDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →